A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Barinthus Biotherapeutics's Debt-to-EBITDA or its related term are showing as below:
STU:2AB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.31 Med: -0.18 Max: 1.69
Current: -0.23
During the past 7 years, the highest Debt-to-EBITDA Ratio of Barinthus Biotherapeutics was 1.69. The lowest was -3.31. And the median was -0.18.
STU:2AB's Debt-to-EBITDA is ranked worse than 100% of 292
companies
in the Biotechnology industry
Industry Median: 1.205
vs STU:2AB: -0.23
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Barinthus Biotherapeutics Debt-to-EBITDA Related Terms
Barinthus Biotherapeutics Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Barinthus Biotherapeutics (STU:2AB) has a Debt-to-EBITDA of -0.59 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Barinthus Biotherapeutics. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 292 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Debt-to-EBITDA too high?
Barinthus Biotherapeutics' current Debt-to-EBITDA is -0.59. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 292 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Debt-to-EBITDA compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 292 companies for Debt-to-EBITDA. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.21, based on 292 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Barinthus Biotherapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Debt-to-EBITDA is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Debt-to-EBITDA of -0.59. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current Debt-to-EBITDA is -0.59. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Debt-to-EBITDA is -0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
Debt-to-EBITDA: -0.59
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
